CSS
NAVB

Cubist Systematic Strategies’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Cubist Systematic Strategies’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,003
Closed -$920 – 4223
2023
Q2 		$920 Buy
+10,003
New +$1.59K ﹤0.01% 3368
2015
Q2 		– Sell
-1,129
Closed -$36K – 2171
2015
Q1 		$36K Buy
+1,129
New +$38.2K ﹤0.01% 1787

Other funds holding NAVB

ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Cubist Systematic Strategies's NAVB Position: Q3 2023 in Review

Cubist Systematic Strategies sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2023, closing a stake of 10,003 shares — an estimated $920 sold.

Cubist Systematic Strategies first reported a position in NAVB in Q1 2015 and held it in 2 quarters. The position peaked at $36K in Q1 2015. 24 funds tracked by Wall St. Rank hold NAVB as of Q3 2023.

  • Cubist Systematic Strategies reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 10,003 Navidea Biopharmaceuticals Inc. shares in Q3 2023, an estimated $920.
  • Cubist Systematic Strategies first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2015 and held it in 2 quarters.
  • Cubist Systematic Strategies's Navidea Biopharmaceuticals Inc. position peaked at $36K in Q1 2015.
  • 24 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2023.

Based on Cubist Systematic Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.